Optimizing the immunogenicity of HIV prime-boost DNA-MVA-rgp140/GLA vaccines in a phase II randomized factorial trial design

Edna O. Viegas ,Arne Kroidl ,Patricia J. Munseri,Marco Missanga,Charlotta Nilsson,Nelson Tembe,Asli Bauer,Agricola Joachim,Sarah Joseph,Philipp Mann,Christof Geldmacher,Sue Fleck,Wolfgang Stöhr,Gabriella Scarlatti,Said Aboud,Muhammad Bakari,Leonard Maboko,Michael Hoelscher,Britta Wahren,Merlin L. Robb,Jonathan Weber,Sheena McCormack,Gunnel Biberfeld,Ilesh V. Jani,Eric Sandström,Eligius Lyamuya,TaMoVac study group

We evaluated the safety and immunogenicity of (i) an intradermal HIV-DNA regimen given with/without intradermal electroporation (EP) as prime and (ii) the impact of boosting with modified vaccinia virus Ankara (HIV-MVA) administered with or without subtype C CN54rgp140 envelope protein adjuvanted with Glucopyranosyl Lipid A (GLA-AF) in volunteers from Tanzania and Mozambique........

Published at:  2018-11-29

Xpert MTB/RIF Ultra assay for the diagnosis of pulmonary tuberculosis in children: a multicentre comparative accuracy study

Authors: Issa Sabi a 1, Andrea Rachow b c 1, Daniel Mapamba a, Petra Clowes a, Nyanda E. Ntinginya a, Mohamed Sasamalo d, Lujeko Kamwela d, Frederick Haraka d e f, Michael Hoelscher b c, Daniel H. Paris e f, Elmar Saathoff b c, Klaus Reither d e f

We evaluated the diagnostic performance of the novel next-generation Xpert MTB/RIF Ultra (Xpert Ultra) in comparison to Xpert MTB/RIF (Xpert) assay for the detection of paediatric pulmonary tuberculosis in high burden settings.

Published at:  2018-10-04

Phenotypic Changes on Mycobacterium Tuberculosis-Specific CD4 T Cells as Surrogate Markers for Tuberculosis Treatment Efficacy

Mohamed I. M. Ahmed1,2,3, Nyanda E. Ntinginya4, Gibson Kibiki5, Bariki A Mtafya4, Hadija Semvua5, Stellah Mpagama5, Charles Mtabho5, Elmar Saathoff1,2, Kathrin Held1,2, Rebecca Loose1,2, Inge Kroidl1,2, Mkunde Chachage1,4, Ulrich von Both1,2,6, Antelmo Haule4, Anna-Maria Mekota1,2, Martin J. Boeree7, Stephen H. Gillespie8, Michael Hoelscher1,2†, Norbert Heinrich1,2† and Christof Geldmacher1,2* on behalf of the Pan African Consortium for the Evaluation of

The analysis of phenotypic characteristics on Mycobacterium tuberculosis (MTB)-specific T cells is a promising approach for the diagnosis of active tuberculosis (aTB) and for monitoring treatment success. We therefore studied phenotypic changes on MTB-specific CD4 T cells upon anti-tuberculosis treatment initiation in relation to the treatment response as determined by sputum culture.

Published at:  2018-09-28

Mate Yako Afya Yako: Formative research to develop the Tanzania HIV self-testing education and promotion (Tanzania STEP) project for men

Donaldson F. Conserve ,Kathryn E. Muessig,Leonard L. Maboko,Sylvia Shirima,Mrema N. Kilonzo,Suzanne Maman,Lusajo Kajula

The purpose of this formative research, guided by the Integrated Behavioral Model, was to assess men’s attitudes and personal agency towards HIV self-testing (HIVST) and confirmatory HIV testing in order to inform the development of the Tanzania STEP (Self-Testing Education and Promotion) Project, a peer-based HIV self-testing intervention for young men in Tanzania. Qualitative in-depth interviews were conducted with 23 men in Dar es Salaam, Tanzania who socialize in networks locally referred to as “camps”. Men reported privacy, confidentiality, and saving time as the primary reasons for their self-testing interest. Most participants had high........

Published at:  2018-08-27

Accuracy and Operational Characteristics of Xpert Human Immunodeficiency Virus Point-of-Care Testing at Birth and Until Week 6 in Human Immunodeficiency Virus–exposed Neonates in Tanzania

Authors: Issa Sabi, Hellen Mahiga, Jimson Mgaya, Otto Geisenberger, Sabine Kastner, Willyhelmina Olomi, Elmar Saathoff, Lilian Njovu, Cornelia Lueer, John France, Leonard Maboko, Nyanda Elias Ntinginya, Michael Hoelscher, Arne Kroidl

Point-of-care (PoC) systems for early infant diagnosis (EID) may improve timely infant human immunodeficiency virus (HIV) management. Experiences within African public health settings are limited.

Published at:  2018-06-29

Reduction of malaria prevalence after introduction of artemisinin-combination-therapy in Mbeya Region, Tanzania: results from a cohort study with 6773 participants

Authors: Guenter Froeschl, Elmar Saathoff, Inge Kroidl, Nicole Berens-Riha, Petra Clowes, Leonard Maboko, Weston Assisya, Wolfram Mwalongo, Martina Gerhardt, Elias Nyanda Ntinginya & Michael Hoelscher Malaria Journal

A marked decline in malaria morbidity and mortality has been reported after the introduction of artemisinin-based combination therapy (ACT) in high malaria prevalence countries in Africa. Data on the impact of ACT and on the prevalence of malaria has so far been scarce for Southwest Tanzania.

Published at:  2018-06-26

The impact of repeated NALC/NaOH- decontamination on the performance of Xpert MTB/RIF assay

Authors: Andrea Rachow a b, Elmar Saathoff a b, Bariki Mtafya c, Daniel Mapamba c, Chacha Mangu c, Gabriel Rojas-Ponce c, Nyanda E. Ntinginya c, Martin Boeree d, Norbert Heinrich a, Stephen H. Gillespie e, Michael Hoelscher a b, PanACEA-Consortium

The Xpert MTB/RIF assay detects Mycobacterium tuberculosis in unprocessed or NALC/NaOH- decontaminated sputum. The effect of repeated NALC/NaOH-decontamination on several Xpert performance parameters was assessed in this study. A second NALC/NaOH-decontamination had no effect on the binary Xpert-outcome but increased the value for the quantitative readout (CTmin). Repeated decontamination was not associated with PCR-inhibition or invalid results. The CTmin of M.tb positive samples was ............

Published at:  2018-05-15

Safety and Immunogenicity of PENNVAX-G DNA Prime Administered by Biojector 2000 or CELLECTRA Electroporation Device With Modified Vaccinia Ankara-CMDR Boost

Julie A Ake, Alexandra Schuetz, Poonam Pegu, Lindsay Wieczorek, Michael A Eller, Hannah Kibuuka, Fredrick Sawe, Leonard Maboko, Victoria Polonis, Nicos Karasavva, David Weiner, Arthur Sekiziyivu, Josphat Kosgei, Marco Missanga, Arne Kroidl, Philipp Mann, Silvia Ratto-Kim, Leigh Anne Eller, Patricia Earl, Bernard Moss, Julie Dorsey-Spitz, Mark Milazzo, G Laissa Ouedraogo, Farrukh Rizvi, Jian Yan, Amir S Khan, Sheila Peel, Niranjan Y Sardesai, Nelson L Michael, Viseth Ngauy, Mary Marovich, Merlin L Robb

We report the first-in-human safety and immunogenicity evaluation of PENNVAX-G DNA/modified vaccinia Ankara–Chiang Mai double recombinant (MVA-CMDR) prime-boost human immuonodeficiency virus (HIV) vaccine, with intramuscular DNA delivery by either Biojector 2000 needle-free injection system (Biojector) or CELLECTRA electroporation device.

Published at:  2017-11-01

Proceedings from the CIHLMU 5th Infectious Diseases Symposium 2016 “Drug Resistant Tuberculosis: Old Disease – New Challenge”

Authors: Celso Khosa, Krutarth Patel, Karlygash Abdiyeva, Nurkeldi Turebekov, Bettina Prüller & Norbert Heinrich

The 5th CIHLMU Infectious Disease Symposium, Munich, Germany, March 12, 2016 brought together Tuberculosis Experts from developed and low middle-income countries to discuss the control of drug resistance Tuberculosis. The meeting featured 9 presentations: Tuberculosis history and current scenario, Tuberculosis and migration - current scenario in Germany, Mechanism of Tuberculosis resistance development, Epidemiology of resistance – transmission vs. new generation of resistance, The impact of diagnostic in patients beyond – sensitivity and specificity, The Bangladesh regimen – new hope trough old drugs, New drugs and regimens – an overview on studies and Multi and Extensively Drug Resistant Tuberculosis from Europe. The presentations were followed by a panel discussion. Serious Multidrug Resistance epidemic in some countries may jeopardize the progress in Tuberculosis control. In this meeting epidemiology, mechanism, immigration and screening, diagnosis, research and treatment of drug resistant tuberculosis were discussed.

Published at:  2017-09-04

Publication Archive

  • 2023 (6 publications)
  • 2022 (12 publications)
  • 2021 (5 publications)
  • 2020 (2 publications)
  • 2019 (2 publications)
  • 2018 (7 publications)
  • 2017 (8 publications)
  • 2016 (7 publications)
  • 2015 (7 publications)
  • 2014 (5 publications)
  • 2013 (5 publications)
  • 2012 (3 publications)
  • 2011 (4 publications)
  • 2010 (5 publications)
  • 2009 (5 publications)
  • 2008 (3 publications)
  • 2007 (3 publications)
  • 2006 (2 publications)
  • 2005 (2 publications)
  • 2004 (2 publications)
  • 2001 (1 publications)